z-logo
open-access-imgOpen Access
Cabergoline Induced Supraventricular Tachycardia with QT Prolongation
Author(s) -
Vineetha Bharathan Me,
Bhanuvaishnavi Gaddipati,
Venkatesh Chandrasekaran,
Pratibha Pereira,
Hathur Basavanna Gowdappa,
Madhan Ramesh
Publication year - 2017
Publication title -
indian journal of pharmacy practice
Language(s) - English
Resource type - Journals
ISSN - 0974-8326
DOI - 10.5530/ijopp.10.2.30
Subject(s) - medicine , cabergoline , prolongation , supraventricular tachycardia , cardiology , tachycardia , anesthesia , hormone , prolactin
Background: Cabergoline is commonly known to cause valvular disorders. Cases of supraventricular tachycardia with QT prolongation are seen, albeit, extremely rare. Aim: We report a case of supraventricular tachycardia with QT prolongation presumed secondary to cabergoline use. Clinical Details: A 30-year-old post-partal female complained of palpitation and syncope after two days of cabergoline usage. Her past medical history was insignificant. Electrocardiogram showed QT prolongation of 489 ms. Based on her presentation, we presume that the patient’s condition was the result of cabergoline. Outcomes: Causality assessment was suggestive of a probable relationship between the patient’s symptoms and her use of cabergoline. Symptoms improved significantly after the offending drug was withdrawn with an objective reduction in QTc. Conclusion: Electrocardiogram should be monitored in individuals receiving more than one QT prolonging medication or with symptoms of arrhythmia or are at high risk of QT prolongation/Torsades de Pointes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom